CD19 and carcinoma: While this goal is very difficult to achieve for carcinomas, melanomas and sarcomas, in hematological malignancies such as B cell leukemia, normal B cell differentiation antigens such CD20 or CD19 can serve as tumor targets because B cells can be replenished from hematopoietic stem cells.